JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer-Reference-Cited by-同舟云学术

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

Published:2021-09-03 Issue:1 Volume:128 Page:65-74
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ramalingam Suresh S.¹^ORCID,Thara Eddie²,Awad Mark M.³,Dowlati Afshin⁴,Haque Basir⁵,Stinchcombe Thomas E.⁶^ORCID,Dy Grace K.⁷,Spigel David R.⁸,Lu Sharon⁹,Iyer Singh Nithya⁹,Tang Yongqiang⁹,Teslenko Iryna⁹,Iannotti Nicholas¹⁰

Affiliation:

1. Emory UniversityWinship Cancer Institute Atlanta Georgia

2. Oncology Institute of Hope and Innovation Los Angeles California

3. Dana‐Farber Cancer Institute Boston Massachusetts

4. University Hospitals Seidman Cancer Center and Case Western Reserve University Cleveland Ohio

5. Kadlec Clinic Hematology and Oncology Kennewick Washington

6. Duke Cancer Institute Duke University School of Medicine Durham North Carolina

7. Roswell Park Comprehensive Cancer Center Buffalo New York

8. Sarah Cannon Research Institute/Tennessee Oncology Nashville Tennessee

9. GlaxoSmithKline Waltham Massachusetts

10. Hematology Oncology Associates of the Treasure Coast Port St. Lucie Florida

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33885

Reference30 articles.

1. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

2. PD-1/PD-L1 Axis in Lung Cancer

3. Keytruda (pembrolizumab) prescribing information. Accessed May 1 2021.https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf

4. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

5. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of SBRT plus immunotherapy on immune status and survival quality of NSCLC patients: A study of combined radiotherapy and immunotherapy;Technology and Health Care;2024-07-29

2. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy;Journal of Oncology Pharmacy Practice;2024-07-26

3. Dostarlimab: Review on success story and clinical trials;Critical Reviews in Oncology/Hematology;2024-06

4. Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors;Biomedicine & Pharmacotherapy;2024-06

5. Future Direction of the Development of Immunotherapy for Lung Cancer;Haigan;2024-02-20